↓ Skip to main content

An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, April 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 928)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
57 news outlets
blogs
7 blogs
twitter
43 X users
wikipedia
4 Wikipedia pages
video
1 YouTube creator

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
113 Mendeley
Title
An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen
Published in
Allergy, Asthma & Clinical Immunology, April 2018
DOI 10.1186/s13223-018-0239-8
Pubmed ID
Authors

B. Bonnet, K. Messaoudi, F. Jacomet, E. Michaud, J. L. Fauquert, D. Caillaud, B. Evrard

Abstract

Cats are the major source of indoor inhalant allergens after house dust mites. The global incidence of cat allergies is rising sharply, posing a major public health problem. Ten cat allergens have been identified. The major allergen responsible for symptoms is Fel d 1, a secretoglobin and not a lipocalin, making the cat a special case among mammals. Given its clinical predominance, it is essential to have a good knowledge of this allergenic fraction, including its basic structure, to understand the new exciting diagnostic and therapeutic applications currently in development. The recent arrival of the component-resolved diagnosis, which uses molecular allergens, represents a unique opportunity to improve our understanding of the disease. Recombinant Fel d 1 is now available for in vitro diagnosis by the anti-Fel d 1 specific IgE assay. The first part of the review will seek to describe the recent advances related to Fel d 1 in terms of positive diagnosis and assessment of disease severity. In daily practice, anti-Fel d 1 IgE tend to replace those directed against the overall extract but is this attitude justified? We will look at the most recent arguments to try to answer this question. In parallel, a second revolution is taking place thanks to molecular engineering, which has allowed the development of various forms of recombinant Fel d 1 and which seeks to modify the immunomodulatory properties of the molecule and thus the clinical history of the disease via various modalities of anti-Fel d 1-specific immunotherapy. We will endeavor to give a clear and practical overview of all these trends.

X Demographics

X Demographics

The data shown below were collected from the profiles of 43 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 113 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 113 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 17%
Researcher 17 15%
Student > Master 11 10%
Student > Ph. D. Student 8 7%
Student > Postgraduate 6 5%
Other 12 11%
Unknown 40 35%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 23 20%
Medicine and Dentistry 16 14%
Chemistry 8 7%
Immunology and Microbiology 6 5%
Agricultural and Biological Sciences 4 4%
Other 13 12%
Unknown 43 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 516. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2024.
All research outputs
#49,854
of 25,703,943 outputs
Outputs from Allergy, Asthma & Clinical Immunology
#3
of 928 outputs
Outputs of similar age
#1,159
of 344,197 outputs
Outputs of similar age from Allergy, Asthma & Clinical Immunology
#1
of 17 outputs
Altmetric has tracked 25,703,943 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 928 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,197 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.